Navigation Links
European Society for Medical Oncology and European CanCer Organization join forces
Date:4/9/2008

Lugano, Switzerland and Brussels, Belgium, 9 April 2008: The European Society for Medical Oncology (ESMO) and ECCO - the European CanCer Organisation have united forces to host a co-branded biennial multidisciplinary partnership meeting that will provide the best and most updated scientific data for everyone working in cancer and will also strengthen initiatives aimed at providing all cancer patients with equal access to high-quality cancer care.

The ECCO Congress, which takes place every two years, will become a joint ECCO-ESMO congress, and its scientific committee will be chaired both by ECCO and ESMO. The first congress will be 20-24 September 2009 in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years.

In the intervening even-numbered years between the ECCO-ESMO congresses, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, 12-16 September, in Stockholm, Sweden.

In addition, ESMOs Board of Directors unanimously voted on 4 April to become a founding member of the new ECCO organisation, composed of European cancer societies, and as a result, ESMO will have a seat on the ECCO Board of Directors. The ECCO Board unanimously accepted the proposal two weeks ago.

ECCO President, Professor Alexander M.M. Eggermont, said he was delighted. ESMO and ECCO have been discussing this for some time now, and we firmly believe that joining forces in this way will benefit all our member organisations, European cancer professionals and, most importantly, cancer patients.

With so much happening in Europe affecting advances in oncology, we need to work together when interacting with European policymakers and industry, so that they take notice, understand and act on our messages. ECCOs mission is to uphold the right of all cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. Together with ESMO, I am confident that we will be able to achieve this goal.

ESMO President, Professor Jos Baselga agreed, and added: This uniting of the landscape of European oncology is the result of an agreement on common goals combined with a strong spirit of goodwill and collaboration on all sides. In becoming a founding member of ECCO, we are convinced we will strengthen our ability to represent European oncologists and patients. ESMO is a community of professionals who share the common goal of providing the best possible care for all cancer patients a mission which is in total harmony with ECCOs objectives.

This is a win-win situation for ESMO, ECCO and all of our patients. I am looking forward to liaising closely with Professor Eggermont, not only in supporting medical oncology and cancer treatment by multidisciplinary teams, but also in working towards enhancing European conferences as attractive settings to present research done in Europe and worldwide. Looking ahead, we will combine our efforts to make the 2009 ECCO 15 34th ESMO Congress the best and biggest European cancer congress yet.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
2. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
3. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
4. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
5. Gene expression differences between Europeans and Africans affect response to drugs, infections
6. Space sentinels: New tools in space to improve European environment and security policies
7. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
8. Specialty European Pharma launches plenaxis in Germany
9. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
10. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
11. European Neuroscience and Society Network tackles neurosocieties head-on
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: